Metformin protects from oxaliplatin induced peripheral neuropathy in rats.
Ontology highlight
ABSTRACT: Oxaliplatin is a commonly used drug to treat cancer, extending the rate of disease-free survival by 20% in colorectal cancer. However, oxaliplatin induces a disabling form of neuropathy resulting in more than 60% of patients having to reduce or discontinue oxaliplatin, negatively impacting their chance of survival. Oxaliplatin-induced neuropathies are accompanied by degeneration of sensory fibers in the epidermis and hyperexcitability of sensory neurons. These morphological and functional changes have been associated with sensory symptoms such as dysesthesia, paresthesia and mechanical and cold allodynia. Various strategies have been proposed to prevent or treat oxaliplatin-induced neuropathies without success. The anti-diabetic drug metformin has been recently shown to exert neuroprotecti
SUBMITTER: Martinez NW
PROVIDER: S-EPMC7260677 | biostudies-literature | 2020 Aug-Dec
REPOSITORIES: biostudies-literature
ACCESS DATA